Led by EssilorLuxottica, a five-year research and innovation project aims to set a new standard in the med-technology space with personalised myopia treatment through medical optics.
Bringing together technical, clinical and digital expertise from leading healthcare, research and industry organisations, the initiative, PREMYOM (Prise en charge et Ralentissement de l’Epidémie de MYopie par l’Optique Médicale – Management and Slowing down of the Myopia Epidemic through Medical Optics), will seek to provide a better understanding of the clinical and biological mechanisms behind myopia progression to deliver widely accessible, advanced, personalised ophthalmic solutions.
The initiative, whose partners include Hôpital Fondation Adolphe de Rothschild, Inria, InSimo, IMT and Institut de la Vision, will tap into cutting-edge research on retinal biology, large-scale cohort studies, clinical trials and big-data analytics. “It will also leverage advanced digital modelling and biomechanical simulation of the myopic eye, innovative optical concepts, as well as next-generation lens manufacturing technologies and optometry instruments,” the partners said in a statement.
